Tarsus Pharmaceuticals (TARS) Receivables - Other (2019 - 2026)

Tarsus Pharmaceuticals' Receivables - Other history runs 8 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 876.43% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (up 876.43% YoY), while the FY2025 annual figure was $2.1 million, up 57.97% from the prior year.
• Receivables - Other for Q1 2026 stood at $16.9 million, up from $336000.0 in the prior quarter.
• The five-year high for Receivables - Other was $16.9 million in Q1 2026, with the low at -$3.2 million in Q1 2023.
• The 5-year median for Receivables - Other is $1.1 million (2024), against an average of $1.9 million.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other surged 7886.96% in 2022, then plunged 1134.31% in 2023.
• Tarsus Pharmaceuticals' Receivables - Other stood at $3.6 million in 2022, then slumped by 97.65% to $84000.0 in 2023, then surged by 83.33% to $154000.0 in 2024, then surged by 118.18% to $336000.0 in 2025, then jumped by 4918.75% to $16.9 million in 2026.
• Business Quant data shows TARS's Receivables - Other at $16.9 million in Q1 2026, $336000.0 in Q4 2025, and $1.7 million in Q3 2025.